Skip to content

DR26 DataRelease

Release Date: 05/07/2018

SDY984: Zoster vaccine in young and elderly
Status: New
Description: Study objective: To analyze the generic innate immune signatures that correlate with the magnitude of the adaptive immune responses (by gamma-interferon ELISPOT, responder-cell frequency (RCF) and flow cytometric studies) in young and elderly populations in order to identify the correlation signatures of the innate immune responses to Zoster vaccine.Study design: Double center, open label study in which adult healthy volunteers will be vaccinated with Zoster vaccine. Blood samples will be collected during a screening visit (between days D-56 to D-14) D0 (at vaccination) and D1, D3, D7, D14, D30, D90 and D180 post vaccination to study innate and adaptive immunity responses. Even though Zoster vaccine is considered safe, volunteers are asked to report and record any local or systemic AEs for 7 days post-vaccination. Also AEs will be reported for 30 days post-vaccination any SAE for 180 days post vaccination. AEs developing the day of the blood draw will also be reported
Program/Contract:
ProgramContract
Human Immunology Project Consortium 2 (HIPC2) Systems Biological Analysis of Innate and Adaptive Responses to Vaccination HIPC2
DOI: 10.21430/M36N1BYFT5
Subjects: 77
Study PI, contact:
NameOrganizationSite
Nadine Rouphael Emory Hope Clinic Emory
Myron Levin Vaccine Research Trials Center Denver
Publications:
Metabolic Phenotypes of Response to Vaccination in Humans.. Cell. May 2017. doi: 10.1016/j.cell.2017.04.026. Epub 2017 May 11. [Pubmed: 28502771]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISA 411
ELISPOT 368
Flow Cytometry 1166
Luminex xMAP 100
Mass Spectrometry 360
Q-PCR 306
Transcription profiling by array 288
Clinical Assessments:None
SDY1217: AFR in drug resistance of cisplatin in bladder cancer
Status: New
Description: Mechanistic study of why elevated tumor suppressor ARF expression in aggressive subtypes of Muscle-invasive bladder cancer (MIBC) is associated with poor outcome and attenuated response to chemotherapy (cisplatin). The study was investigated In both GEMM and murine xenograft models of human MIBC. Resistance was mediated in part by the integrin-binding protein ITGB3BP (CENPR) and reflected ARF-dependent impairment of protein translation, which was exaggerated by drug treatment.
Program/Contract:
ProgramContract
Enhance Applicability of Mouse Models for Translational Research (Oncology Model, OMF) Analysis of drug response in organoids and mouse models (Oncology Model, OMF)
DOI: 10.21430/M3I9QJDMAU
Subjects: 24
Study PI, contact:
NameOrganizationSite
Cory Abate-Shen Columbia University Medical Center Department of Medicine
Publications:
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.. Cancer Res. Feb 2017. doi: 10.1158/0008-5472.CAN-16-2621. Epub 2017 Jan 12. [Pubmed: 28082400]
Resources:
PRJNA353384 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA353384]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 24
Clinical Assessments:None
SDY1249: Whole tumor RNA-sequencing and deconvolution of glioma transcriptional signature
Status: New
Description: Using whole tumor RNA-sequencing and mathematical deconvolution strategies to characterize low-grade glioma exosystem of several preclinical mouse models of neurofibromatosis type 1 (NF1) optic glioma, a low-grade astrocytoma whose formation and maintenance requires productive interactions between non-neoplastic and neoplastic cells. The result demonstrate that optic gliomas generated by altering the germline Nf1 gene mutation, the glioma cell of origin, or the presence of co-existing genetic alterations represent molecularly-distinct tumors. However, these optic glioma tumors share a 25-gene core signature, not found in normal optic nerve, that is normalized by microglia inhibition (minocycline), but not conventional (carboplatin) or molecularly-targeted (rapamycin) chemotherapy. In addition, a genetic signature conferred by Pten reduction and corrected by PI3K inhibition was identified, which predicts progression-free survival in patients with either low-grade or high-grade glioma. Collectively, these findings support the concept that gliomas are composite ecological systems whose biology and response to therapy may be best defined by examining the tumor as a whole.
Program/Contract:
ProgramContract
Enhance Applicability of Mouse Models for Translational Research (Oncology Model, OMF) Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management
DOI: 10.21430/M3FP7GYREE
Subjects: 67
Study PI, contact:
NameOrganizationSite
David Gutmann Washington University School of Medicine Department of Neurology
Publications:
Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.. Oncotarget. Apr 2017. doi: 10.18632/oncotarget.17193. eCollection 2017 Aug 8. [Pubmed: 28881745]
Resources:
PRJNA397467 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA397467]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 67
Clinical Assessments:None
SDY1290: Dendritic Cell Maturation Dynamics
Status: New
Description: Maturation and migration to lymph nodes (LNs) constitutes a central paradigm in conventional dendritic cell (cDC) biology but remains poorly defined in humans. Using our organ donor tissue resource, we analyzed cDC subset distribution, maturation, and migration in mucosal tissues (lungs, intestines), associated lymph nodes (LNs), and other lymphoid sites from 78 individuals ranging from less than 1 year to 93 years of age. The distribution of cDC1 (CD141hiCD13hi) and cDC2 (Sirp-?+CD1c+) subsets was a function of tissue site and was conserved between donors. We identified cDC2 as the major mature (HLA-DRhi) subset in LNs with the highest frequency in lung-draining LNs. Mature cDC2 in mucosal-draining LNs expressed tissue-specific markers derived from the paired mucosal site, reflecting their tissue-migratory origin. These distribution and maturation patterns were largely maintained throughout life, with site-specific variations. Our findings provide evidence for localized DC tissue surveillance and reveal a lifelong division of labor between DC subsets, with cDC2 functioning as guardians of the mucosa.
Program/Contract:
ProgramContract
Tissue compartmentalization of human lymphocytes P01AI106697 Tissue compartmentalization of human lymphocytes
DOI: 10.21430/M3T9R8JS6G
Subjects: 77
Study PI, contact:
NameOrganizationSite
Donna Farber Columbia University Columbia University Medical Center
Publications:
Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life. Immunity March 2017. doi: 10.1016/j.immuni.2017.02.019 [Pubmed: 28329707]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 763
Clinical Assessments:None
SDY1298: EZH2 as an Therapy Target in Lung Cancer
Status: New
Description: As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers. Overexpression of EZH2 is commonly observed in human epithelial cancers. The paper demonstrated the causal role of EZH2 overexpression in NSCLC with humEZH2 in mouse models of lung adenocarcinoma, which featured distinct transcription program from KRAS- and EGFR models. To target EZH2-dependent cancers, the lab designed an open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in preclinical studies in EZH2-driven models.
Program/Contract:
ProgramContract
Enhance Applicability of Mouse Models for Translational Research (Oncology Model, OMF) Credentialing Mouse Models for Immune System Therapy Research (Oncology Model, OMF)
DOI: 10.21430/M3G6V89CIE
Subjects: 7
Study PI, contact:
NameOrganizationSite
Kowk Wong Dana-Farber Cancer Institute, Harvard Medical School Department of Medical Oncology
James Bradner Dana-Farber Cancer Institute, Harvard Medical School Department of Medical Oncology
Publications:
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.. Cancer Discov. Sep 2016. doi: 10.1158/2159-8290.CD-16-0164. Epub 2016 Jun 16. [Pubmed: 27312177]
Resources:
PRJNA287534 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA287534]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 7
Clinical Assessments:None
SDY1324: Transcriptomic Analysis of CD4+ T Cells Reveals Novel Immune Signatures of Latent Tuberculosis. (See SDY820 for corresponding PBMC results.)
Status: New
Description: The human immune signature of latent Mycobacterium tuberculosis infected patients as well as BCG vaccinated and BCG non-vaccinated individuals was studied by RNA sequencing
Program/Contract:
ProgramContract
Human Immunology Project Consortium 2 (HIPC2) Human immune signatures of dengue virus and mycobacterium tuberculosis exposure in infection; disease and vaccination (HIPC2)
DOI: 10.21430/M3VYDM1MIM
Subjects: 60
Study PI, contact:
NameOrganizationSite
Bjoern Peters La Jolla Institute for Allergy and Immunology La Jolla Institute for Allergy and Immunology
Publications:
Transcriptomic Analysis of CD4+ T Cells Reveals Novel Immune Signatures of Latent Tuberculosis.. J Immunol. Mar 2018. doi: - [Pubmed: 29602771]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 119
Clinical Assessments:None
SDY1326: A proteomic clock of human pregnancy
Status: New
Description: Advances in multiplexed platform technologies facilitated exploration of human plasma proteins in term pregnancies indicating the existence of a proteomic clock
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M3C9848DA7
Subjects: 31
Study PI, contact:
NameOrganizationSite
Martin Angst March of Dimes Prematurity Research Center at Stanford University School of Medicine March of Dimes Prematurity Research Center at Stanford University School of Medicine
Nima Aghaeepour March of Dimes Prematurity Research Center at Stanford University School of Medicine March of Dimes Prematurity Research Center at Stanford University School of Medicine
Publications:
A proteomic clock of human pregnancy.. Am J Obstet Gynecol. Mar 2018. doi: 10.1016/j.ajog.2017.12.208. Epub 2017 Dec 24. [Pubmed: 29277631]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Other 122
Clinical Assessments:None
SDY1327: Adaptive and innate immunity in sPTB
Status: New
Description: This study is a meta-analysis evaluating differential gene expression signals in spontaneous preterm birth (sPTB). Three studies related to sPTB with maternal whole blood samples were selected in publicly available datasets, resulting in data from 339 samples. A meta-analysis of the aggregated and normalized transcriptomic datasets led to identification of 210 genes differentially expressed in sPTB relative to term birth. These genes were enriched in immune related pathways, showing upregulation of innate immunity and downregulation of adaptive immunity in women who delivered preterm. Additional analyses identified potential clinically relevant biomarkers.
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M30O36DLJZ
Subjects: 0
Study PI, contact:
NameOrganizationSite
Marina Sirota Institute for Computational Health Sciences, University of California, San Francisco, California Institute for Computational Health Sciences, University of California, San Francisco, California
Publications:
Meta-Analysis of Maternal and Fetal Transcriptomic Data Elucidates the Role of Adaptive and Innate Immunity in Preterm Birth.. Front Immunol. May 2018. doi: 10.3389/fimmu.2018.00993. eCollection 2018. [Pubmed: 29867970]
Resources:
Data Visualization http://comphealth.ucsf.edu/preterm_transcriptomics/]
Whole blood gene expression profile associated with spontaneous preterm birth https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46510]
Maternal Whole Blood Gene Expression at 18 and 28 weeks of Gestation Associated with Spontaneous Preterm Birth in Asymptomatic Women https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59491]
Unique inflammatory transcriptome profiles at the maternal fetal interface and onset of human preterm and term birth https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73685]
Assays:None
Clinical Assessments:None
SDY112: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2011 (See companion studies SDY311 2010 / SDY312 2009 / SDY314 2008 / SDY315 2012)
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M320H8XYFG
Subjects: 93
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford University School of Medicine
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 95
DNA microarray 89
Flow Cytometry 744
Hemagglutination Inhibition 181
Luminex xMAP 352
Clinical Assessments:None
SDY113: Plasmablast response to inactivated and live attenuated influenza vaccines (TIV3/TIV3 ID/LAIV) in 2011
Status: Updated
Description: To study the plasmablast response to influenza vaccines
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3KPFS7KXI
Subjects: 70
Study PI, contact:
NameOrganizationSite
Harry Greenberg Stanford University Stanford University
Publications:
Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines.. J Infect Dis. Sep 2014. doi: 10.1093/infdis/jiu190. Epub 2014 Mar 27. [Pubmed: 24676204]
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02141581]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 61
DNA microarray 57
ELISA 60
ELISPOT 60
Flow Cytometry 358
Hemagglutination Inhibition 128
Luminex xMAP 374
Clinical Assessments:None
SDY183: Effect of age on 2008/2009 trivalent influenza vaccine response
Status: Updated
Description: To comprehensively compare the humoral immune response of young (20-31 years old) to older human subjects (60 to >90 years old) following vaccination with seasonal flu vaccine. We generated a peptide microarray featuring tiled peptides with sequences derived from the hemagglutinin proteins of multiple influenza strains. We probed the microarrays with pre- and post-vaccination serum from each age group. Serum antibody reactivity to the microarray peptides was quantified using fluorescently labeled anti-human secondary antibodies and a fluorescent microarray scanner.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M37TU3LVTU
Subjects: 76
Study PI, contact:
NameOrganizationSite
PJ Utz Stanford University Stanford
Publications:
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness.. Mol Syst Biol. Apr 2013. doi: 10.1038/msb.2013.15. [Pubmed: 23591775]
Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.. PLoS One. May 2013. doi: 10.1371/journal.pone.0064555. Print 2013. [Pubmed: 23734205]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43446]
Immune Epitope Database (IEDB) http://www.iedb.org/reference/1027229]
Assays:
Assay TypeNumber of Exp. Samples
Protein microarray 152
Clinical Assessments:None
SDY212: Apoptosis and other immune biomarkers predict influenza vaccine (TIV 2008) responsiveness
Status: Updated
Description: Despite the importance of the immune system in many diseases, there are currently no objective benchmarks of immunological health. In an effort to indentify benchmarks of immunological health, influenza vaccination was used in 30 young (20-30 years) and 59 older subjects (60 to 89 years) as models for strong and weak immune responses, respectively. Serological responses to influenza strains as well as a wide variety of other parameters, including gene expression, antibodies to hemagglutinin peptides, serum cytokines, cell subset phenotypes and in vitro cytokine stimulation were measured. Using machine learning, nine variables predicting antibody response with 84% accuracy were identified. Two of these variables are involved in apoptosis, which positively associated with the response to vaccination and was confirmed to be a contributor to vaccine responsiveness in mice. The identification of these biomarkers provides new insights into what immune features may be most important for immune health.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M37NGTHMDS
Subjects: 91
Study PI, contact:
NameOrganizationSite
Mark M. Davis Stanford University Stanford-LPCH Vaccine Program
Publications:
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness.. Mol Syst Biol. Apr 2013. doi: 10.1038/msb.2013.15. [Pubmed: 23591775]
Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires.. J Immunol. Jan 2014. doi: 10.4049/jimmunol.1301384. Epub 2013 Dec 11. [Pubmed: 24337376]
Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans.. Cell Syst. Oct 2016. doi: 10.1016/j.cels.2016.09.009. Epub 2016 Oct 13. [Pubmed: 27746093]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41080]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 1086
Hemagglutination Inhibition 534
Luminex xMAP 91
Protein microarray 91
Transcription profiling by array 91
Clinical Assessments:None
SDY289: Live Kidney Donor Study (RELIVE-01)
Status: Updated
Description: The purpose of this study was to establish a multi-center kidney donor database containing renal failure, cardiovascular and overall mortality information for the complete cohorts of kidney donors who underwent living donor uninephrectomy.
Program/Contract:
ProgramContract
RELIVE CLINICAL OUTCOMES OF LIVE ORGAN DONORS - DATA COORDINATING CENTER
DOI: 10.21430/M3DM0S6FPM
Subjects: 8922
Study PI, contact:
NameOrganizationSite
Sandra Taler Division of Nephrology and Hypertension, Mayo Clinic Mayo Clinic
Publications:
Living donor age and kidney transplant outcomes.. Am J Transplant. Jun 2011. doi: 10.1111/j.1600-6143.2011.03552.x. Epub 2011 May 12. [Pubmed: 21564530]
Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades.. Am J Transplant. Feb 2013. doi: 10.1111/j.1600-6143.2012.04321.x. Epub 2012 Nov 8. [Pubmed: 23137211]
Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study.. Am J Transplant. Nov 2013. doi: 10.1111/ajt.12434. Epub 2013 Sep 6. [Pubmed: 24011252]
Satisfaction With Life Among Living Kidney Donors: A RELIVE Study of Long-Term Donor Outcomes.. Transplantation. Dec 2014. doi: 10.1097/TP.0000000000000360. [Pubmed: 25136843]
Emotional well-being of living kidney donors: findings from the RELIVE Study.. Am J Transplant. Nov 2014. doi: 10.1111/ajt.12906. Epub 2014 Oct 7. [Pubmed: 25293374]
Emotional and Financial Experiences of Kidney Donors over the Past 50 Years: The RELIVE Study.. Clin J Am Soc Nephrol. Dec 2015. doi: 10.2215/CJN.07120714. Epub 2015 Oct 13. [Pubmed: 26463883]
Resources:
Clinicaltrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00608283]
NIH RePORTER http://projectreporter.nih.gov/project_info_details.cfm?aid=7099092&icde=26162432]
Assays:None
Clinical Assessments:None
SDY290: Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study (RELIVE-04)
Status: Updated
Description: The goal of this study is to determine the long-term risks of donor nephrectomy, compared to appropriate control subjects. This study built on information generated from RELIVE-01, a separate but related retrospective study. Through direct contact with previous living kidney donors this study examined the contribution of living kidney donation to the future development of hypertension, proteinuria, renal insufficiency or renal failure and anemia, the potential through these factors or others for increased cardiovascular risk for clinical events including myocardial infarction (MI), congestive heart failure (CHF), need for coronary artery bypass grafting (CABG) or percutaneous coronary angioplasty (PTCA) revascularization, and the impact of living kidney donation on quality of life (QOL) and financial status, compared to applicable control subjects and populations.
Program/Contract:
ProgramContract
RELIVE CLINICAL OUTCOMES OF LIVE ORGAN DONORS - DATA COORDINATING CENTER
DOI: 10.21430/M39RJDHJVB
Subjects: 196
Study PI, contact:
NameOrganizationSite
Sandra Taler Division of Nephrology and Hypertension, Mayo Clinic Mayo Clinic
Publications:
Living donor age and kidney transplant outcomes.. Am J Transplant. Jun 2011. doi: 10.1111/j.1600-6143.2011.03552.x. Epub 2011 May 12. [Pubmed: 21564530]
Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades.. Am J Transplant. Feb 2013. doi: 10.1111/j.1600-6143.2012.04321.x. Epub 2012 Nov 8. [Pubmed: 23137211]
Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study.. Am J Transplant. Nov 2013. doi: 10.1111/ajt.12434. Epub 2013 Sep 6. [Pubmed: 24011252]
Satisfaction With Life Among Living Kidney Donors: A RELIVE Study of Long-Term Donor Outcomes.. Transplantation. Dec 2014. doi: 10.1097/TP.0000000000000360. [Pubmed: 25136843]
Emotional well-being of living kidney donors: findings from the RELIVE Study.. Am J Transplant. Nov 2014. doi: 10.1111/ajt.12906. Epub 2014 Oct 7. [Pubmed: 25293374]
Emotional and Financial Experiences of Kidney Donors over the Past 50 Years: The RELIVE Study.. Clin J Am Soc Nephrol. Dec 2015. doi: 10.2215/CJN.07120714. Epub 2015 Oct 13. [Pubmed: 26463883]
Resources:
Clinicaltrials.gov http://www.clinicaltrials.gov/ct2/show/study/NCT00951977]
NIH RePORTER http://projectreporter.nih.gov/project_info_details.cfm?aid=7099092&icde=26162432]
Assays:None
Clinical Assessments:None
SDY291: Live Kidney Donor Study -Renal Function Study (RELIVE-06)
Status: Updated
Description: As part of a cross-sectional study of living kidney donors from 5 to more than 50 years following donor nephrectomy, this study's goal is to accurately measure current Glomerular Filtration Rate (GFR), then to look at the change in GFR from pre to post donation and from early to late time points after donation. This study builds on information generated from RELIVE-01 and RELIVE-04. Through direct contact with previous living kidney donors, this study aims to quantify changes in renal function (measured GFR) from pre to early post donation using data already collected in a related retrospective study (RELIVE 01), and the change in renal function from early (in the first 2 years) post donation to late (beyond the first 2 years) post donation by repeating a GFR measurement. Cross-sectional GFR measurements from black donors compared to white donors matched for age, sex, weight and time from donation will provide data on differences in GFR late after donor nephrectomy by race. When compared to GFR estimates using predictive equations at each of these time points, we can evaluate the accuracy of estimated GFR in white and black donor populations.
Program/Contract:
ProgramContract
RELIVE CLINICAL OUTCOMES OF LIVE ORGAN DONORS - DATA COORDINATING CENTER
DOI: 10.21430/M33MG60QVQ
Subjects: 413
Study PI, contact:
NameOrganizationSite
Sandra Taler Division of Nephrology and Hypertension, Mayo Clinic Mayo Clinic
Publications:
Living donor age and kidney transplant outcomes.. Am J Transplant. Jun 2011. doi: 10.1111/j.1600-6143.2011.03552.x. Epub 2011 May 12. [Pubmed: 21564530]
Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades.. Am J Transplant. Feb 2013. doi: 10.1111/j.1600-6143.2012.04321.x. Epub 2012 Nov 8. [Pubmed: 23137211]
Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study.. Am J Transplant. Nov 2013. doi: 10.1111/ajt.12434. Epub 2013 Sep 6. [Pubmed: 24011252]
Satisfaction With Life Among Living Kidney Donors: A RELIVE Study of Long-Term Donor Outcomes.. Transplantation. Dec 2014. doi: 10.1097/TP.0000000000000360. [Pubmed: 25136843]
Emotional well-being of living kidney donors: findings from the RELIVE Study.. Am J Transplant. Nov 2014. doi: 10.1111/ajt.12906. Epub 2014 Oct 7. [Pubmed: 25293374]
Emotional and Financial Experiences of Kidney Donors over the Past 50 Years: The RELIVE Study.. Clin J Am Soc Nephrol. Dec 2015. doi: 10.2215/CJN.07120714. Epub 2015 Oct 13. [Pubmed: 26463883]
Resources:
Clinicaltrials.gov http://www.clinicaltrials.gov/ct2/show/NCT01158742]
NIH RePORTER http://projectreporter.nih.gov/project_info_details.cfm?aid=7099092&icde=26162432]
Assays:None
Clinical Assessments:None
SDY305: Plasmablast response to inactivated and live attenuated influenza vaccines (TIV3/TIV3 ID) in 2012
Status: Updated
Description: To study the plasmablast response to 2012 seasonal inactivated influenza vaccine
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3U2R9IV87
Subjects: 25
Study PI, contact:
NameOrganizationSite
Harry Greenberg Stanford University Stanford University
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02141581]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 23
DNA microarray 24
ELISA 23
ELISPOT 23
Flow Cytometry 296
Hemagglutination Inhibition 48
Luminex xMAP 30
Clinical Assessments:None
SDY311: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011)
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M33MSDRJ55
Subjects: 76
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 79
DNA microarray 73
Flow Cytometry 464
Hemagglutination Inhibition 140
Luminex xMAP 426
Clinical Assessments:None
SDY312: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2009 (See companion studies SDY315 2012 / SDY314 2008 / SDY311 2010 / SDY112 2011)
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3G230OYOM
Subjects: 84
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:
Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans.. Cell Syst. Oct 2016. doi: 10.1016/j.cels.2016.09.009. Epub 2016 Oct 13. [Pubmed: 27746093]
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 73
Flow Cytometry 1155
Hemagglutination Inhibition 158
Luminex xMAP 484
Clinical Assessments:None
SDY314: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2008 (See companion studies SDY315 2012 / SDY312 2009 / SDY311 2010 / SDY112 2011)
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3WZ7XK2GG
Subjects: 92
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 91
Flow Cytometry 445
Hemagglutination Inhibition 178
HLA Typing 81
Virus Neutralization 178
Clinical Assessments:None
SDY315: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2012 (See companion studies SDY311 2010 / SDY312 2009 / SDY314 2008 / SDY112 2011)
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3CJT3NCT2
Subjects: 74
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 74
DNA microarray 71
Flow Cytometry 408
Hemagglutination Inhibition 136
Luminex xMAP 138
Clinical Assessments:None
SDY395: Immune Responses to Influenza-Like Illness
Status: Updated
Description: To investigate the nasal transcriptional response and peripheral plasmablast response in acute influenza infection
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M33RY4IXN7
Subjects: 33
Study PI, contact:
NameOrganizationSite
Harry Greenberg Stanford School of Medicine Stanford School of Medicine
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
Luminex xMAP 62
Clinical Assessments:None
SDY460: B and T Cell Determinants of Influenza Vaccine Responses in the Elderly 2008 (see companion study SDY773)
Status: Updated
Description: Application of high-throughput DNA sequencing of the IGH gene rearrangements to study the B cell repertoires over two successive years in 27 individuals ranging in age from 20 to 89 years old.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M34OUDCFO2
Subjects: 27
Study PI, contact:
NameOrganizationSite
Scott Boyd Stanford University School of Medicine Stanford University School of Medicine
Publications:
Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires.. J Immunol. Jan 2014. doi: 10.4049/jimmunol.1301384. Epub 2013 Dec 11. [Pubmed: 24337376]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
BioProject http://www.ncbi.nlm.nih.gov/bioproject/PRJNA222239]
Assays:
Assay TypeNumber of Exp. Samples
Sequencing 1296
Clinical Assessments:None
SDY472: Plasmablast response to inactivated and live attenuated influenza vaccines (TIV3/TIV3 ID) in 2013
Status: Updated
Description: This study will be conducted with up to 40 generally healthy children
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3KHTSSSN7
Subjects: 24
Study PI, contact:
NameOrganizationSite
Harry Greenberg Stanford University Stanford University
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT02141581]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 24
Hemagglutination Inhibition 136
Luminex xMAP 46
Clinical Assessments:None
SDY478: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination - 2013
Status: Updated
Description: Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3YEJTSS29
Subjects: 70
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:None
Resources:
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 73
Hemagglutination Inhibition 544
Luminex xMAP 138
Clinical Assessments:None
SDY514: Monozygotic and Dizygotic Twin Pair T-Cell Responses to Influenza Vaccination 2009
Status: Updated
Description: Evaluate the variation in immune response between individuals and assess whether it changes as a function of age and similarity in genetic and environmental background (by comparing differences between monozygotic and dizygotic twin pairs of different ages).
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3M6BADC48
Subjects: 74
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:
Variation in the human immune system is largely driven by non-heritable influences.. Cell. Jan 2015. doi: 10.1016/j.cell.2014.12.020. [Pubmed: 25594173]
Resources:
Brodin Lab.github Twin data visualization http://brodinlab.github.io/Twin_data_visualization/biocells.html]
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT01987349]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 991
Hemagglutination Inhibition 150
Luminex xMAP 613
Clinical Assessments:None
SDY515: Monozygotic and Dizygotic Twin Pair T-Cell Responses to Influenza Vaccination 2010
Status: Updated
Description: Evaluate the variation in immune response between individuals and assess whether it changes as a function of age and similarity in genetic and environmental background (by comparing differences between monozygotic and dizygotic twin pairs of different ages).
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3RDGZH60O
Subjects: 84
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:
Variation in the human immune system is largely driven by non-heritable influences.. Cell. Jan 2015. doi: 10.1016/j.cell.2014.12.020. [Pubmed: 25594173]
Resources:
Brodin Lab.github Twin data visualization http://brodinlab.github.io/Twin_data_visualization/biocells.html]
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT03022396]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 88
Flow Cytometry 400
Hemagglutination Inhibition 156
Luminex xMAP 523
Clinical Assessments:None
SDY519: Monozygotic and Dizygotic Twin Pair T-Cell Responses to Influenza Vaccination 2011
Status: Updated
Description: Evaluate the variation in immune response between individuals and assess whether it changes as a function of age and similarity in genetic and environmental background (by comparing differences between monozygotic and dizygotic twin pairs of different ages).
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3TI6PGH9Q
Subjects: 63
Study PI, contact:
NameOrganizationSite
Mark Davis Stanford University Stanford-LPCH Vaccine Program
Publications:
Variation in the human immune system is largely driven by non-heritable influences.. Cell. Jan 2015. doi: 10.1016/j.cell.2014.12.020. [Pubmed: 25594173]
Resources:
Brodin Lab.github Twin data visualization http://brodinlab.github.io/Twin_data_visualization/biocells.html]
clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT03022422]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 127
Flow Cytometry 432
Hemagglutination Inhibition 118
Luminex xMAP 396
Clinical Assessments:None
SDY675: Heritable influence on the B and T cell receptor repertoire
Status: Updated
Description: The adaptive immune systems capability to protect the body requires a highly diverse lymphocyte antigen receptor repertoire. However, the influence of individual genetic and epigenetic differences on these repertoires is frequently underestimated. By leveraging the unique characteristics of B, CD4+ T, and CD8+ T lymphocyte subsets isolated from monozygotic twins, we have elucidated the impact of heritable factors on the V(D)J recombination process and have shown that the repertoires of both naive and antigen experienced cells are subject to biases resulting from initial recombination differences. Moreover, we show that the relative usage of V and J gene segments is chromosomally biased, with approximately 1.5 times as many rearrangements originating from a single chromosome. These data refine our understanding of the heritable mechanisms affecting the repertoire, and show that bias exists on a chromosome-wide level.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M3XMYVQI9X
Subjects: 10
Study PI, contact:
NameOrganizationSite
Mark M Davis Stanford University Stanford University
Publications:
Individual heritable differences result in unique cell lymphocyte receptor repertoires of naive and antigen-experienced cells.. Nat Commun. Mar 2016. doi: 10.1038/ncomms11112. [Pubmed: 27005435]
Resources:
NCBI BIOPROJECT http://www.ncbi.nlm.nih.gov/bioproject/PRJNA300878]
VDJ Server Homo sapiens B and T cell repertoire - MZ twins https://vdjserver.org/community/531076969703215591-242ac11c-0001-012/metadata]
Assays:
Assay TypeNumber of Exp. Samples
Sequencing 10
Clinical Assessments:None
SDY773: B and T Cell Determinants of Influenza Vaccine Responses in the Elderly 2009 (see companion study SDY460)
Status: Updated
Description: Application of high-throughput DNA sequencing of the IGH gene rearrangements to study the B cell repertoires over two successive years in 27 individuals ranging in age from 20 to 89 years old.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M35OPGLUTH
Subjects: 27
Study PI, contact:
NameOrganizationSite
Scott Boyd Stanford University School of Medicine Stanford University School of Medicine
Publications:
Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires.. J Immunol. Jan 2014. doi: 10.4049/jimmunol.1301384. Epub 2013 Dec 11. [Pubmed: 24337376]
Resources:
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01827462]
BioProject http://www.ncbi.nlm.nih.gov/bioproject/PRJNA222239]
Assays:
Assay TypeNumber of Exp. Samples
Sequencing 1296
Clinical Assessments:None
SDY887: Defective signaling in aging
Status: Updated
Description: Pilot year. Despite the importance of the immune system in many diseases, there are currently no objective benchmarks of immunological health. In an effort to indentify benchmarks of immunological health, influenza vaccination was used in 10 young (20-30 years) and 19 older subjects (60 to 89 years) as models for strong and weak immune responses, respectively. Serological responses to influenza strains as well as a wide variety of other parameters, including gene expression, antibodies to hemagglutinin peptides, serum cytokines, cell subset phenotypes and in vitro cytokine stimulation were measured. Using machine learning, nine variables predicting antibody response with 84% accuracy were identified. Two of these variables are involved in apoptosis, which positively associated with the response to vaccination and was confirmed to be a contributor to vaccine responsiveness in mice. The identification of these biomarkers provides new insights into what immune features may be most important for immune health.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M33JMYFLF1
Subjects: 26
Study PI, contact:
NameOrganizationSite
Cornelia Dekker Stanford University Stanford University
Publications:
Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans.. Cell Syst. Oct 2016. doi: 10.1016/j.cels.2016.09.009. Epub 2016 Oct 13. [Pubmed: 27746093]
Resources:
Department of Pediatrics- Infectious Diseases Stanford University School of Medicine http://med.stanford.edu/pedsid/contact.html]
Shen-Orr Lab, Technion http://shenorrlab.technion.ac.il/]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 208
Clinical Assessments:None
SDY888: Human Immune Signature of Dengue virus infection- Gene Expression of CD4 subsets
Status: Updated
Description: The human Immune Signature of Dengue virus infection was studied in two endemic areas. T cell responses were compared in infected patients and uninfected individuals also from Dengue endemic areas.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 2 (HIPC2) Human immune signatures of dengue virus and mycobacterium tuberculosis exposure in infection; disease and vaccination (HIPC2)
DOI: 10.21430/M3C4L4WD2Z
Subjects: 79
Study PI, contact:
NameOrganizationSite
Alessandro Sette La Jolla Institute for Allergy and Immunology La Jolla Institute for Allergy and Immunology
Publications:
Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA.. Nat Commun. Nov 2017. doi: 10.1038/s41467-017-01728-5. [Pubmed: 29133794]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 74
Clinical Assessments:None
SDY997: AMP Lupus Network Project: Molecular Characterization of Lupus Nephritis and Correlation with Response to Therapy
Status: Updated
Description: Phase I will be devoted to the study of at least 45 subjects with lupus nephritis and 25 controls with the intent of achieving the following goals: (i) to assess feasibility of obtaining a sufficient yield of high quality data based on current and refined AMP SOPs, (ii) to assess recruitment rates and the number of sites necessary to effectively recruit for Phase II, (iii) to ensure that the technologies developed in Phase 0 are working well, especially with regard to transport and scaling up to handle specimens from multiple sites; (iv) to demonstrate that the selected technologies can be used for the purpose of reliably differentiating lupus nephritis kidneys from kidney tissue without lupus nephritis, (v) where necessary, to further refine the technologies before embarking on a large-scale project; and most importantly (vi) to provide critical data upon which to make rational decisions about key elements of the Phase II study design (e.g., eligibility criteria, estimates of variation for power calculations, and site-specific capability regarding patient recruitment, specimen handling, etc.).
Program/Contract:
ProgramContract
Accelerating Medicines Partnership (AMP) Accelerating Medicines Partnership (AMP)
DOI: 10.21430/M35FLWNXH1
Subjects: 105
Study PI, contact:
NameOrganizationSite
PJ Utz Stanford PEARL
Michael Holers Colorado PEARL
Publications:None
Resources:
NIH AMP RA/SLE Program https://www.niams.nih.gov/Funding/Funded_Research/AMP_RA_Lupus/default.asp]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 259
Flow Cytometry 171
RNA sequencing 13415
Clinical Assessments:
SLE Assessments
SDY998: AMP Rheumatoid Arthritis Arthroplasty Phase 1
Status: Updated
Description: The primary goal for RA arthroplasty P1 studies are: To establish if molecular signatures and pathways identified using core AMP technologies differ between OA and RA in 20 RA surgical samples and 10 OA arthroplasty samples.
Program/Contract:
ProgramContract
Accelerating Medicines Partnership (AMP) Accelerating Medicines Partnership (AMP)
DOI: 10.21430/M3KXJHSP4T
Subjects: 40
Study PI, contact:
NameOrganizationSite
Jennifer Anolik Rochester Rochester
Vivian Bykerk HSS HSS
Larry Moreland Pittsburg Pittsburg
Michael Holers Colorado Colorado
Peter Gregersen Northwell Northwell
Gary Firestein UCSD UCSD
PJ Utz Stanford Stanford
Michael Weisman Cedars Sinai Cedars Sinai
Publications:None
Resources:
NIH AMP RA/SLE Program https://www.niams.nih.gov/Funding/Funded_Research/AMP_RA_Lupus/default.asp]
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 105
Flow Cytometry 136
Microscopy 192
RNA sequencing 3856
Clinical Assessments:
Medical History
SDY999: AMP Rheumatoid Arthritis Synovial Phase 1
Status: Updated
Description: The primary goal for RA synovial P1 studies are: To establish feasibility of obtaining ultrasound-guided synovial biopsies in the United States (U.S.) by comparing to frozen synovial biopsies obtained in the United Kingdom (U.K.)
Program/Contract:
ProgramContract
Accelerating Medicines Partnership (AMP) Accelerating Medicines Partnership (AMP)
DOI: 10.21430/M3XRJHRPBC
Subjects: 22
Study PI, contact:
NameOrganizationSite
Jennifer Anolik Rochester Rochester
Vivian Bykerk HSS HSS
Gary Firestein UCSD UCSD
Peter Gregersen Northwell Northwell
Michael Holers Colorado Colorado
Larry Moreland Pittsburg Pittsburg
PJ Utz Stanford Stanford
Publications:None
Resources:
Assays:
Assay TypeNumber of Exp. Samples
CyTOF 70
Flow Cytometry 173
Microscopy 229
RNA sequencing 6333
Clinical Assessments:
Medical History
SDY1172: Systems Immunology of Malaria
Status: Updated
Description: Immunity to malaria can be acquired through natural exposure to Plasmodium falciparum (Pf), but only after years of repeated infections. Typically, this immunity is acquired by adolescence and confers protection against disease, but Pf infection per se. Efforts to understand the mechanisms of this immunity are integral to the development of a vaccine that would mimic the induction of adult immunity in children. The current study applies systems biology approaches to a cohort from the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal. Signatures that correlate with protection from malaria may yield new hypotheses regarding the biological mechanisms through which malaria immunity is induced by natural Pf infection. The resulting datasets will be of considerable value in the urgent worldwide effort to develop a malaria vaccine that could prevent more than a million deaths annually.
Program/Contract:
ProgramContract
NIAID Laboratory of Immunogenetics NIAID Laboratory of Immunogenetics
DOI: 10.21430/M3CFFNO2V3
Subjects: 80
Study PI, contact:
NameOrganizationSite
Peter Crompton NIH / NIAID / LIG NIH / NIAID / LIG
Publications:
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clinical Infectious Diseases July 2013. doi: 10.1093/cid/cit174 [Pubmed: 23487390]
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.. Journal of Infectious Diseases March 2014. doi: 10.1093/infdis/jit553 [Pubmed: 24133188]
Co-infection of long-term carriers of Plasmodium falciparum with Schistosoma haematobium enhances protection from febrile malaria: a prospective cohort study in Mali.. PLoS Neglected Tropical Diseases September 2014. doi: 10.1371/journal.pntd.0003154 [Pubmed: 25210876]
A nested real-time PCR assay for the quantification of Plasmodium falciparum DNA extracted from dried blood spots. Malaria Journal October 2014. doi: 10.1186/1475-2875-13-393 [Pubmed: 25282516]
Gut microbiota elicits a protective immune response against malaria transmission. Cell December 2014. doi: 10.1016/j.cell.2014.10.053 [Pubmed: 25480293]
Impact of acute malaria on pre-existing antibodies to viral and vaccine antigens in mice and humans. PLoS One April 2015. doi: 10.1371/journal.pone.0125090 [Pubmed: 25919588]
Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection. BMC Genomics August 2015. doi: 10.1186/s12864-015-1819-3 [Pubmed: 26296559]
Circulating Th1-Cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute malaria in children. Cell Reports October 2015. doi: 10.1016/j.celrep.2015.09.004 [Pubmed: 26440897]
Transcriptome evidence for modulation of host inflammatory response during febrile P. falciparum malaria. Scientific Reports August 2016. doi: 10.1038/srep31291 [Pubmed: 27506615]
Treatment of chronic asymptomatic Plasmodium falciparum infection does not increase the risk of clinical malaria upon reinfection. Clinical Infectious Diseases March 2017. doi: 10.1093/cid/ciw849 [Pubmed: 28362910]
Public antibodies to malaria antigens generated by two LAIR1 insertion modalities. Nature August 2017. doi: 10.1038/nature23670 [Pubmed: 28847005]
Resources:
Trials.gov https://clinicaltrials.gov/ct2/show/study/NCT01322581]
RNA-seq GEO https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52166]
Assays:
Assay TypeNumber of Exp. Samples
RNA sequencing 151
Clinical Assessments:
Febrile Mal
Protection Status
Temperature
SDY1176: Extensive homeostatic T cell phenotypic variation within the Collaborative Cross
Status: Updated
Description: The Collaborative Cross (CC) is a panel of reproducible recombinant inbred mouse strains with high levels of standing genetic variation, thereby affording unprecedented opportunity to perform experiments in a small animal model containing controlled genetic diversity while allowing for genetic replicates. Here, we advance the utility of this unique mouse resource for immunology research, as it allows for both examination and genetic dissection of mechanisms behind adaptive immune states in mice with distinct and defined genetic makeups. This approach is founded on quantitative trait locus mapping: identifying genetically variant genome regions associated with phenotypic variance in traits-of-interest. Furthermore, the CC can be utilized for mouse model development; distinct strains have unique immunophenotypes and immune properties, making them suitable for research on particular diseases and infections. Here, we describe variation in cellular immune phenotypes across F1 crosses of CC strains, and reveal novel quantitative trait loci responsible for several immune phenotypes.
Program/Contract:
ProgramContract
Systems Approach to Immunity and Inflammation Systems Immunogenetics of Biodefense Pathogens in the Collaborative Cross
DOI: 10.21430/M3RKBKOYKS
Subjects: 476
Study PI, contact:
NameOrganizationSite
Jennifer Lund Fred Hutchinson Cancer Research Center Vaccine and Infectious Disease Division
Publications:None
Resources:
https://research.fhcrc.org/lund/en.html Dr. Jennifer Lund's Lab]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 822
Clinical Assessments:None
SDY1206: Early pregnancy vaginal microbiome trends and preterm birth (see companion study SDY1341)
Status: Updated
Description: Previous studies have shown that vaginal microbiota of asymptomatic, nonpregnant, reproductive age women cluster into 5 distinct ?community-state types?, which differ both by dominant Lactobacillus species as well as overall community composition. A much greater proportion of African-American and Hispanic women harbored a non-Lactobacillus-dominant community, suggesting that in some women a non-Lactobacillus-based vaginal community may be a normal variant. A recent study examined vaginal microbial composition and the risk for preterm birth but had very few African-American subjects and few preterm births. This study characterizes vaginal microbial community characteristics over time in a large predominantly African-American cohort of pregnant women and test whether particular community characteristics are associated with the risk for subsequent preterm birth.
Program/Contract:
ProgramContract
March of Dimes March of Dimes Human Microbiome
DOI: 10.21430/M3H1U3KJMZ
Subjects: 77
Study PI, contact:
NameOrganizationSite
Methodius Tuuli Washington University in St Louis School of Medicine, St. Louis, MO Washington University in St Louis School of Medicine, St. Louis, MO
Molly Stout Washington University in St Louis School of Medicine, St. Louis, MO Washington University in St Louis School of Medicine, St. Louis, MO
Publications:
Early pregnancy vaginal microbiome trends and preterm birth.. Am J Obstet Gynecol. Sep 2017. doi: 10.1016/j.ajog.2017.05.030. Epub 2017 May 23. [Pubmed: 28549981]
Resources:
SRA ? Microbiome Data https://www.ncbi.nlm.nih.gov/bioproject/PRJNA294119/]
Assays:
Assay TypeNumber of Exp. Samples
16S rRNA gene sequencing 149
Clinical Assessments:
Pregnancy History